Roche NimbleGen introduces enhanced whole exome sequencing solution for medical and translational research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Roche NimbleGen introduced an enhanced whole exome sequencing solution for medical and translational research.

Roche announced the global launch of the SeqCap EZ MedExome Target Enrichment Kit, a comprehensive whole exome sequencing solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs.

Pekka Ellonen, head of the sequencing unit for the Institute for Molecular Medicine Finland at the University of Helsinki, said, “We have evaluated a number of target enrichment systems for whole exome sequencing.

The kit is labeled “for research use only. It isn’t approved for diagnostic procedures.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login